The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial
Abstract
IMPORTANCE: Secretory phospholipase A2 (sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2 inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2 inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measure was a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95% CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95% CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2 inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Update on acute coronary syndromes: the pathologists' view
Falk, E., Nakano, M., Bentzon, J. F., Finn, A. V., & Virmani, R. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs411 · Cited by 1,047
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
Ivandic, B., Castellani, L. W., Wang, X.-P., Qiao, J.-H., Mehrabian, M., Navab, M., Fogelman, A. M., Grass, D. S., Swanson, M. E., de Beer, M. C., et al. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1284 · Cited by 244
Phospholipase A2 enzymes and the risk of atherosclerosis
Rosenson, R. S., & Hurt‐Camejo, E. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs148 · Cited by 147
Self-citationSecretory group II phospholipase A2 in human atherosclerotic plaques
Menschikowski, M., Kasper, M. E., Lattke, P., Schiering, A., Schiefer, S., Stockinger, H., & Jaroß, W. (1995) · Atherosclerosis · doi:10.1016/0021-9150(95)05604-1 · Cited by 130
White, H. D., Held, C., Stewart, R., Watson, D. I., Harrington, R. A., Budaj, A., Steg, P. G., Cannon, C. P., Krug‐Gourley, S., Wittes, J. T., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.07.006 · Cited by 125
Cited by
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes, M. V., Ala-Korpela, M., & Smith, G. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.78 · Cited by 679
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Myocardial ischemia-reperfusion injury and the influence of inflammation
Algoet, M., Janssens, S., Himmelreich, U., Gsell, W., Pusovnik, M., Van den Eynde, J., & Oosterlinck, W. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.02.005 · Cited by 545
Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.185 · Cited by 477
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions
Raggi, P., Genest, J., Giles, J. T., Rayner, K. J., Dwivedi, G., Beanlands, R. S., & Gupta, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.014 · Cited by 433
Metadata
- Authors
- Nicholls, S. J., Kastelein, J. J. P., Schwartz, G. G., Bash, D., Rosenson, R. S., Cavender, M. A., Brennan, D. M., Koenig, W., Jukema, J. W., Nambi, V., Wright, R. S., Menon, V., Lincoff, A. M., & Nissen, S. E.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-01-15
- Volume
- 311
- Issue
- 3
- Pages
- 252
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2124964328
- Cited by
- 344
- References
- 19
- FWCI
- 33.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2013.282836
- The paper
- Nicholls, S. J., Kastelein, J. J. P., Schwartz, G. G., Bash, D., Rosenson, R. S., Cavender, M. A., Brennan, D. M., Koenig, W., Jukema, J. W., Nambi, V., Wright, R. S., Menon, V., Lincoff, A. M., & Nissen, S. E. (2014). Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome: The VISTA-16 Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2013.282836
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.